# US 2021/0172923 A1 · Devices, compositions and methods for use in detecting contaminating heavy metals in water sources

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172923 A1
- Document ID: US20210172923A1
- Status: Published application
- Kind: A1
- Application number: 17/247,247
- Filed: 2020-12-04
- Published: 2021-06-10
- Earliest claimed: 2019-12-06
- Applicants: Spout
- Inventors: Ari Kaufman; Robert A. Masinter; Diane A. Blake; Joseph Kaeller; Bart J. Massee; Brian Heinze
- Web page: https://patentgrep.com/patent/US20210172923A1

## CPC

- G01N 33/54388: {based on lateral flow}
- B01L 3/508: {Rigid containers without fluid transport within}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- G01N 21/78: producing a change of colour
- G01N 33/1813: {Specific cations in water, e.g. heavy metals}
- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- G01N 33/84: involving inorganic compounds or pH
- B01L 2200/026: Fluid interfacing between devices or objects, e.g. connectors, inlet details
- G01N 2021/7759: {Dipstick; Test strip}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to electronic reader devices, detection compositions and methods for detecting heavy metals (e.g., lead) in water samples using a simple, rapid and highly selective immunoassay system, including lateral and upward flow assay systems. The immunoassay is designed to detect very low levels of a contaminating analyte such as lead at less than 1 ppb with high specificity and selectivity from any common water source (e.g., tap or drinking water). Advantageously, implementation of the assay requires no formal technical training or expensive equipment or reagents and is provided with a multi-use reader that can be used for 50 samples or more. The immunoassay sample collector systems are consumable (single use) and can be purchased in any desired quantity. Assay results are wirelessly transmitted from the reader using a SafeSpout-designed app., which provides important information based on the test results.

## Claims

### Claim 1

A method of detecting and quantitating an analyte in a sample comprising the steps of:
a) obtaining a sample potentially containing an analyte of interest;
b) transferring the sample to a sample collector pre-treating the sample to prepare the sample for detection and quantitation of the analyte;
c) contacting the pre-treated sample with a test strip;
d) assaying the pre-treated sample using the test strip to determine the concentration of the analyte in the pre-treated sample; and
e) quantitating the concentration of the analyte, wherein the concentration of the analyte is measured qualitatively and quantitatively using the test strip.

### Claim 2 (depends on 1)

The method of claim 1, wherein the detecting and quantitating of the analyte in the sample comprises an immunoassay test strip, wherein a sample application area and a detection area are on a chromatographic immunoassay test strip, and the test strip further comprises a sample pad, wherein the pre-treated sample is applied to or first contacted with the test strip and a conjugate area or pad, wherein the conjugate pad comprises at least one labeled binding partner that is able to migrate with the sample medium, and a capture area or pad, wherein the capture pad comprises a test line comprising chelator-conjugates and a control line comprising anti-species antibodies, and an absorbant pad, wherein the sample flow terminates.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sample is a liquid sample selected from the group consisting of tap water, well water, unfiltered drinking water, filtered drinking water, household plumbing water contained within pipes, bottled water, municipal water, aquifer water, wastewater including industrial wastewater sources, effluent and river water.

### Claim 4 (depends on 1)

The method of claim 1, wherein the analyte comprises a heavy metal.

### Claim 5 (depends on 4)

The method of claim 4, wherein the heavy metal is selected from lead Pb(II), chromium Cr(II), arsenic Ar(II), cadmium Cd(II), and mercury Hg(II).

### Claim 6 (depends on 5)

The method of claim 5, wherein the heavy metal is lead Pb(II).

### Claim 7 (depends on 5)

The method of claim 5, wherein the heavy metal detection level in the pre-treated sample is at a concentration of between about <1 ppb to about 20 ppb.

### Claim 8 (depends on 7)

The method of claim 7, wherein the concentration of metal in the pre-treated sample is between <1 ppb and about 15 ppb, between <1 ppb and about 8 ppb, between <1 ppb and 5 ppb, between <1 ppb and 2 ppb.

### Claim 9 (depends on 7)

The method of claim 7, wherein the lead Pb(II) concentration in the pre-treated sample is <1 ppb.

### Claim 10 (depends on 1)

The method of claim 1, further comprising the step of: f) determining the concentration level of a metal detected in step d) within 60 minutes of transferring the sample in step b).

### Claim 11 (depends on 10)

The method of claim 10, wherein the concentration level is determined within 45 minutes of transferring the sample in step b).

### Claim 12 (depends on 10)

The method of claim 10, wherein the concentration level is determined within 30 minutes of transferring the sample in step b).

### Claim 13 (depends on 10)

The method of claim 10, wherein the concentration level is determined within 15 minutes of transferring the sample in step b).

### Claim 14 (depends on 2)

The method of claim 2, wherein the at least one binding partner comprises a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a single-chain (scFv) antibody, disulfide-linked Fvs (sdFv), Fab fragments, F(ab′) fragments, or antigen-binding fragments.

### Claim 15 (depends on 14)

The method of claim 14, wherein the monoclonal antibody is the monoclonal antibody designated 2C12, wherein 2C12 comprises light-chain and heavy-chain variable regions.

### Claim 16 (depends on 15)

The method of claim 15, wherein the light-chain and heavy-chain variable regions consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively; wherein the complementarity-determining regions (CDR) in the light chain variable region of 2C12 consist of residues 24-39 (SEQ ID NO: 3), residues 55-61 (SEQ ID NO: 4) and residues 95-103 (SEQ ID NO: 5); and wherein the complementarity-determining regions (CDR) in the heavy-chain variable region of 2C12 consist of residues 26-35 (SEQ ID NO: 6), residues 50-65 (SEQ ID NO: 7) and residues 98-105 (SEQ ID NO: 8).

### Claim 17 (depends on 2)

The method of claim 2, further comprising chelators.

### Claim 18 (depends on 17)

The method of claim 17, wherein the chelators are selected from the group consisting of CHXDTPA, CHXEDTA, EDTA, EGTA, citrate, and ITCBE or the free acids of any of the foregoing.

### Claim 19 (depends on 18)

The method of claim 18, wherein the chelator is CHXDTPA.

### Claim 20 (depends on 1)

The method of claim 1, further comprising detection or labeling reagents.

### Claim 21 (depends on 20)

The method of claim 20, wherein the detection or labeling reagents are selected from the group consisting of gold nanoparticles (AuNP), latex microparticles, reporter groups including horseradish peroxidase (HRP) and alkaline phosphatase (AP), metal sol tags including silver, selenium and carbon.

### Claim 22 (depends on 21)

The method of claim 21, wherein the detection or labeling reagent is gold nanoparticles (AuNP).

### Claim 23

A system for detecting and quantitating an analyte in a sample comprising the steps of:
a) obtaining a sample potentially containing an analyte of interest;
b) transferring the sample to a sample collector for pre-treatment to prepare the sample for detection and quantitation of the analyte;
c) contacting the pre-treated sample with a test strip;
d) assaying the pre-treated sample using the test strip to determine the concentration of the analyte in the sample, wherein the concentration of the analyte is measured qualitatively and quantitatively using the test strip;
e) qualitatively determining the concentration level of a metal detected in step d), wherein the result is determined within 60 minutes, within 45 minutes, within 30 minutes, within 20 minutes or within 15 minutes; and
f) quantitatively determining the concentration level of a metal detected in step d), wherein the metal concentration level is recorded in a multi-use reader device.

### Claim 24 (depends on 23)

The system of claim 23, wherein the concentration data is wirelessly transferred to a smartphone app using a back-end software platform.

### Claim 25 (depends on 23)

The system of claim 23, wherein the sample collector in step b) and parts of the multi-use reader device in step f) are disposable or recyclable.

### Claim 26

A device for detecting and quantitating an analyte in a liquid sample comprising:
an analyte detection reader 100;
a sample collector 110; and
an assay cassette 130, wherein the analyte detection reader is designed to hold the sample collector and the assay cassette for reading a sample.

### Claim 27 (depends on 26)

The device of claim 26, wherein the sample collector further comprises a sample pre-treatment system 112.

### Claim 28 (depends on 27)

The device of claim 27, wherein the sample pre-treatment system 112 comprises:
a water collection chamber 114,
a blister ampoule containing acid 116,
a distribution rod 118,
an ion-exchange resin 120,
a drain 121,
a waste collection chamber 122,
a separation chamber 123,
sample splitting chambers 124,
a blister or equivalent containing neutralizing reagent and chelator(s) 125, sample distribution chambers 126, and
immunoassay strips 128a and 128b, wherein the immunoassay strips detect different concentration ranges of analyte.

### Claim 29 (depends on 28)

The device of claim 28, wherein the immunoassay strips are for detecting and quantitating an analyte comprising:
a base plate 202;
a sample receiving pad 204a and a dried sample treatment pad 204b;
a first conjugate pad area 206a and a second conjugate pad area 206b, wherein the first conjugate pad area and the second conjugate pad area are impregnated with a first binding partner bound to a detection reagent; and wherein the first binding partner bound to the detection reagent is able to flow along the immunoassay strips to an elongated analyte detection capture pad 208;
a first capture area comprising a test line 210 immobilized with analyte chelator-conjugates, wherein the first binding partner bound to a detection reagent competes for binding sites at the test line;
a second capture area comprising a control line 212 immobilized with a second binding partner; and
an absorbent pad 214a and an absorbent reservoir pad 214b, wherein the absorbent pad acts as a wicking mechanism to regulate capillary flow from the sample receiving pad to the absorbent reservoir pad.

### Claim 30 (depends on 29)

The device of claim 29, wherein the first binding partner comprises a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a single-chain (scFv) antibody, disulfide-linked Fvs (sdFv), Fab fragments, F(ab′) fragments, or antigen-binding fragments.

### Claim 31 (depends on 30)

The device of claim 30, wherein the monoclonal antibody is the monoclonal antibody designated 2C12, wherein 2C12 comprises light-chain and heavy-chain variable regions.

### Claim 32 (depends on 31)

The device of claim 31, wherein the light-chain and heavy-chain variable regions consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively; wherein the complementarity-determining regions (CDR) in the light chain variable region of 2C12 consist of residues 24-39 (SEQ ID NO: 3), residues 55-61 (SEQ ID NO: 4) and residues 95-103 (SEQ ID NO: 5); and wherein the complementarity-determining regions (CDR) in the heavy-chain variable region of 2C12 consist of residues 26-35 (SEQ ID NO: 6), residues 50-65 (SEQ ID NO: 7) and residues 98-105 (SEQ ID NO: 8).

### Claim 33 (depends on 29)

The device of claim 29, wherein the second binding partner comprises an anti-species antibody.

### Claim 34 (depends on 29)

The device of claim 29, further comprising chelators.

### Claim 35 (depends on 34)

The device of claim 34, wherein the chelators are selected from the group consisting of CHXDTPA, CHXEDTA, EDTA, EGTA, citrate, and ITCBE or the free acids of any of the foregoing.

### Claim 36 (depends on 35)

The device of claim 35, wherein the chelator is CHXDTPA.

### Claim 37 (depends on 29)

The device of claim 29, further comprising detection or labeling reagents.

### Claim 38 (depends on 37)

The device of claim 37, wherein the detection or labeling reagents are selected from the group consisting of gold nanoparticles (AuNP), latex microparticles, reporter groups including horseradish peroxidase (HRP) and alkaline phosphatase (AP), metal sol tags including silver, selenium and carbon.

### Claim 39 (depends on 38)

The device of claim 38, wherein the detection or labeling reagent is gold nanoparticles (AuNP).
